COVID-19 Impact on Global Targeted Drug VEGF Inhibitors for NSCLC Market Size, Status and Forecast 2020-2026

July 2020 | 92 pages | ID: C9DAEB97608BEN
QYResearch

Abstracts

This report focuses on the global Targeted Drug VEGF Inhibitors for NSCLC status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drug VEGF Inhibitors for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Roche
• Pfizer
• Allergan
• Amgen
• Biocon
• Reliance Lifesciences
• Beaconpharma
• Celgene Corporation
• Fujifilm Kyowa Kirin Biologics
• Hetero Drugs

Market segment by Type, the product can be split into

• Bevacizumab
• Other

Market segment by Application, split into

• Squamous Cell Carcinoma of NSCLC
• Adenocarcinoma of NSCLC
• Large Cell Carcinoma of NSCLC

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Targeted Drug VEGF Inhibitors for NSCLC status, future forecast, growth opportunity, key market and key players.
• To present the Targeted Drug VEGF Inhibitors for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Targeted Drug VEGF Inhibitors for NSCLC are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Targeted Drug VEGF Inhibitors for NSCLC Revenue
1.4 Market Analysis by Type
  1.4.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Bevacizumab
  1.4.3 Other
1.5 Market by Application
  1.5.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application: 2020 VS 2026
  1.5.2 Squamous Cell Carcinoma of NSCLC
  1.5.3 Adenocarcinoma of NSCLC
  1.5.4 Large Cell Carcinoma of NSCLC
1.6 Coronavirus Disease 2019 (Covid-19): Targeted Drug VEGF Inhibitors for NSCLC Industry Impact
  1.6.1 How the Covid-19 is Affecting the Targeted Drug VEGF Inhibitors for NSCLC Industry
    1.6.1.1 Targeted Drug VEGF Inhibitors for NSCLC Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Targeted Drug VEGF Inhibitors for NSCLC Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Targeted Drug VEGF Inhibitors for NSCLC Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Targeted Drug VEGF Inhibitors for NSCLC Market Perspective (2015-2026)
2.2 Targeted Drug VEGF Inhibitors for NSCLC Growth Trends by Regions
  2.2.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Targeted Drug VEGF Inhibitors for NSCLC Historic Market Share by Regions (2015-2020)
  2.2.3 Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Targeted Drug VEGF Inhibitors for NSCLC Market Growth Strategy
  2.3.6 Primary Interviews with Key Targeted Drug VEGF Inhibitors for NSCLC Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Targeted Drug VEGF Inhibitors for NSCLC Players by Market Size
  3.1.1 Global Top Targeted Drug VEGF Inhibitors for NSCLC Players by Revenue (2015-2020)
  3.1.2 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Players (2015-2020)
  3.1.3 Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Concentration Ratio
  3.2.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Targeted Drug VEGF Inhibitors for NSCLC Revenue in 2019
3.3 Targeted Drug VEGF Inhibitors for NSCLC Key Players Head office and Area Served
3.4 Key Players Targeted Drug VEGF Inhibitors for NSCLC Product Solution and Service
3.5 Date of Enter into Targeted Drug VEGF Inhibitors for NSCLC Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Targeted Drug VEGF Inhibitors for NSCLC Historic Market Size by Type (2015-2020)
4.2 Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Type (2021-2026)

5 TARGETED DRUG VEGF INHIBITORS FOR NSCLC BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)
5.2 Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size (2015-2020)
6.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in North America (2019-2020)
6.3 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020)
6.4 North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size (2015-2020)
7.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in Europe (2019-2020)
7.3 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020)
7.4 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)

8 CHINA

8.1 China Targeted Drug VEGF Inhibitors for NSCLC Market Size (2015-2020)
8.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in China (2019-2020)
8.3 China Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020)
8.4 China Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size (2015-2020)
9.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in Japan (2019-2020)
9.3 Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020)
9.4 Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size (2015-2020)
10.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020)
10.4 Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)

11 INDIA

11.1 India Targeted Drug VEGF Inhibitors for NSCLC Market Size (2015-2020)
11.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in India (2019-2020)
11.3 India Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020)
11.4 India Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Size (2015-2020)
12.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in Central & South America (2019-2020)
12.3 Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020)
12.4 Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Roche
  13.1.1 Roche Company Details
  13.1.2 Roche Business Overview and Its Total Revenue
  13.1.3 Roche Targeted Drug VEGF Inhibitors for NSCLC Introduction
  13.1.4 Roche Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020))
  13.1.5 Roche Recent Development
13.2 Pfizer
  13.2.1 Pfizer Company Details
  13.2.2 Pfizer Business Overview and Its Total Revenue
  13.2.3 Pfizer Targeted Drug VEGF Inhibitors for NSCLC Introduction
  13.2.4 Pfizer Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
  13.2.5 Pfizer Recent Development
13.3 Allergan
  13.3.1 Allergan Company Details
  13.3.2 Allergan Business Overview and Its Total Revenue
  13.3.3 Allergan Targeted Drug VEGF Inhibitors for NSCLC Introduction
  13.3.4 Allergan Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
  13.3.5 Allergan Recent Development
13.4 Amgen
  13.4.1 Amgen Company Details
  13.4.2 Amgen Business Overview and Its Total Revenue
  13.4.3 Amgen Targeted Drug VEGF Inhibitors for NSCLC Introduction
  13.4.4 Amgen Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
  13.4.5 Amgen Recent Development
13.5 Biocon
  13.5.1 Biocon Company Details
  13.5.2 Biocon Business Overview and Its Total Revenue
  13.5.3 Biocon Targeted Drug VEGF Inhibitors for NSCLC Introduction
  13.5.4 Biocon Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
  13.5.5 Biocon Recent Development
13.6 Reliance Lifesciences
  13.6.1 Reliance Lifesciences Company Details
  13.6.2 Reliance Lifesciences Business Overview and Its Total Revenue
  13.6.3 Reliance Lifesciences Targeted Drug VEGF Inhibitors for NSCLC Introduction
  13.6.4 Reliance Lifesciences Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
  13.6.5 Reliance Lifesciences Recent Development
13.7 Beaconpharma
  13.7.1 Beaconpharma Company Details
  13.7.2 Beaconpharma Business Overview and Its Total Revenue
  13.7.3 Beaconpharma Targeted Drug VEGF Inhibitors for NSCLC Introduction
  13.7.4 Beaconpharma Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
  13.7.5 Beaconpharma Recent Development
13.8 Celgene Corporation
  13.8.1 Celgene Corporation Company Details
  13.8.2 Celgene Corporation Business Overview and Its Total Revenue
  13.8.3 Celgene Corporation Targeted Drug VEGF Inhibitors for NSCLC Introduction
  13.8.4 Celgene Corporation Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
  13.8.5 Celgene Corporation Recent Development
13.9 Fujifilm Kyowa Kirin Biologics
  13.9.1 Fujifilm Kyowa Kirin Biologics Company Details
  13.9.2 Fujifilm Kyowa Kirin Biologics Business Overview and Its Total Revenue
  13.9.3 Fujifilm Kyowa Kirin Biologics Targeted Drug VEGF Inhibitors for NSCLC Introduction
  13.9.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
  13.9.5 Fujifilm Kyowa Kirin Biologics Recent Development
13.10 Hetero Drugs
  13.10.1 Hetero Drugs Company Details
  13.10.2 Hetero Drugs Business Overview and Its Total Revenue
  13.10.3 Hetero Drugs Targeted Drug VEGF Inhibitors for NSCLC Introduction
  13.10.4 Hetero Drugs Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
  13.10.5 Hetero Drugs Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Targeted Drug VEGF Inhibitors for NSCLC Key Market Segments
Table 2. Key Players Covered: Ranking by Targeted Drug VEGF Inhibitors for NSCLC Revenue
Table 3. Ranking of Global Top Targeted Drug VEGF Inhibitors for NSCLC Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Bevacizumab
Table 6. Key Players of Other
Table 7. COVID-19 Impact Global Market: (Four Targeted Drug VEGF Inhibitors for NSCLC Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for Targeted Drug VEGF Inhibitors for NSCLC Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for Targeted Drug VEGF Inhibitors for NSCLC Players to Combat Covid-19 Impact
Table 12. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Regions (2015-2020)
Table 16. Global Targeted Drug VEGF Inhibitors for NSCLC Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Targeted Drug VEGF Inhibitors for NSCLC Market Growth Strategy
Table 22. Main Points Interviewed from Key Targeted Drug VEGF Inhibitors for NSCLC Players
Table 23. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by Players (2015-2020) (Million US$)
Table 24. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Players (2015-2020)
Table 25. Global Top Targeted Drug VEGF Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug VEGF Inhibitors for NSCLC as of 2019)
Table 26. Global Targeted Drug VEGF Inhibitors for NSCLC by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Targeted Drug VEGF Inhibitors for NSCLC Product Solution and Service
Table 29. Date of Enter into Targeted Drug VEGF Inhibitors for NSCLC Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 32. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Type (2015-2020)
Table 33. Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by Type (2021-2026)
Table 34. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Application (2015-2020)
Table 35. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 36. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Share by Application (2021-2026)
Table 37. North America Key Players Targeted Drug VEGF Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Targeted Drug VEGF Inhibitors for NSCLC Market Share (2019-2020)
Table 39. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 40. North America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 41. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 42. North America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 43. Europe Key Players Targeted Drug VEGF Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Targeted Drug VEGF Inhibitors for NSCLC Market Share (2019-2020)
Table 45. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 47. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 49. China Key Players Targeted Drug VEGF Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 50. China Key Players Targeted Drug VEGF Inhibitors for NSCLC Market Share (2019-2020)
Table 51. China Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 52. China Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 53. China Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 54. China Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 55. Japan Key Players Targeted Drug VEGF Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Targeted Drug VEGF Inhibitors for NSCLC Market Share (2019-2020)
Table 57. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 59. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Targeted Drug VEGF Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Targeted Drug VEGF Inhibitors for NSCLC Market Share (2019-2020)
Table 63. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 65. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 67. India Key Players Targeted Drug VEGF Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 68. India Key Players Targeted Drug VEGF Inhibitors for NSCLC Market Share (2019-2020)
Table 69. India Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 70. India Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 71. India Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 72. India Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Targeted Drug VEGF Inhibitors for NSCLC Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Targeted Drug VEGF Inhibitors for NSCLC Market Share (2019-2020)
Table 75. Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type (2015-2020)
Table 77. Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2015-2020)
Table 79. Roche Company Details
Table 80. Roche Business Overview
Table 81. Roche Product
Table 82. Roche Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 83. Roche Recent Development
Table 84. Pfizer Company Details
Table 85. Pfizer Business Overview
Table 86. Pfizer Product
Table 87. Pfizer Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 88. Pfizer Recent Development
Table 89. Allergan Company Details
Table 90. Allergan Business Overview
Table 91. Allergan Product
Table 92. Allergan Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 93. Allergan Recent Development
Table 94. Amgen Company Details
Table 95. Amgen Business Overview
Table 96. Amgen Product
Table 97. Amgen Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 98. Amgen Recent Development
Table 99. Biocon Company Details
Table 100. Biocon Business Overview
Table 101. Biocon Product
Table 102. Biocon Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 103. Biocon Recent Development
Table 104. Reliance Lifesciences Company Details
Table 105. Reliance Lifesciences Business Overview
Table 106. Reliance Lifesciences Product
Table 107. Reliance Lifesciences Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 108. Reliance Lifesciences Recent Development
Table 109. Beaconpharma Company Details
Table 110. Beaconpharma Business Overview
Table 111. Beaconpharma Product
Table 112. Beaconpharma Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 113. Beaconpharma Recent Development
Table 114. Celgene Corporation Business Overview
Table 115. Celgene Corporation Product
Table 116. Celgene Corporation Company Details
Table 117. Celgene Corporation Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 118. Celgene Corporation Recent Development
Table 119. Fujifilm Kyowa Kirin Biologics Company Details
Table 120. Fujifilm Kyowa Kirin Biologics Business Overview
Table 121. Fujifilm Kyowa Kirin Biologics Product
Table 122. Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 123. Fujifilm Kyowa Kirin Biologics Recent Development
Table 124. Hetero Drugs Company Details
Table 125. Hetero Drugs Business Overview
Table 126. Hetero Drugs Product
Table 127. Hetero Drugs Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020) (Million US$)
Table 128. Hetero Drugs Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Type: 2020 VS 2026
Figure 2. Bevacizumab Features
Figure 3. Other Features
Figure 4. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application: 2020 VS 2026
Figure 5. Squamous Cell Carcinoma of NSCLC Case Studies
Figure 6. Adenocarcinoma of NSCLC Case Studies
Figure 7. Large Cell Carcinoma of NSCLC Case Studies
Figure 8. Targeted Drug VEGF Inhibitors for NSCLC Report Years Considered
Figure 9. Global Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Regions: 2020 VS 2026
Figure 11. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Players in 2019
Figure 14. Global Top Targeted Drug VEGF Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drug VEGF Inhibitors for NSCLC as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Targeted Drug VEGF Inhibitors for NSCLC Revenue in 2019
Figure 16. North America Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 24. Roche Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
Figure 25. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Pfizer Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
Figure 27. Allergan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Allergan Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
Figure 29. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Amgen Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
Figure 31. Biocon Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Biocon Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
Figure 33. Reliance Lifesciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Reliance Lifesciences Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
Figure 35. Beaconpharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Beaconpharma Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
Figure 37. Celgene Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Celgene Corporation Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
Figure 39. Fujifilm Kyowa Kirin Biologics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Fujifilm Kyowa Kirin Biologics Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
Figure 41. Hetero Drugs Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Hetero Drugs Revenue Growth Rate in Targeted Drug VEGF Inhibitors for NSCLC Business (2015-2020)
Figure 43. Bottom-up and Top-down Approaches for This Report
Figure 44. Data Triangulation
Figure 45. Key Executives Interviewed